Personalized Pemafibrate Dosing Regimens for Enhanced Safety and Efficacy

A novel system and method for optimizing pemafibrate dosing regimens in patients taking OATP1B inhibitors, ensuring personalized and safe treatment of dyslipidemia.

The original pemafibrate dosing regimens patent (Patent Literature 1) has limitations in addressing the risk of adverse interactions with OATP1B inhibitors, which can lead to reduced efficacy and increased toxicity. The present inventive concept solves this problem by introducing a system and method for adjusting pemafibrate dosing based on the type and amount of OATP1B inhibitor being administered.

The inventive concept comprises a dosing calculator configured to adjust the daily dose of pemafibrate based on the type and amount of OATP1B inhibitor being administered. This is achieved through a personalized approach, considering the patient's medical history and genetic profile. The system can also provide real-time monitoring of liver enzyme levels, enabling dynamic dose adjustments to ensure safe and effective treatment. The inventive concept can be implemented through various embodiments, including a computer-readable storage medium storing a program for optimizing pemafibrate dosing regimens.

The new claims introduce a novel system and method for optimizing pemafibrate dosing regimens, which is not obvious from the original patent. The inventive concept's personalized approach and real-time monitoring capabilities provide a significant improvement over existing pemafibrate dosing regimens.

Alternative embodiments of the inventive concept may include mobile applications, wearable devices, or cloud-based platforms for optimizing pemafibrate dosing regimens. Variations of the system may incorporate machine learning algorithms to predict optimal dosing regimens based on patient data and medical history.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of dyslipidemia. The system and method can be licensed to pharmaceutical companies, hospitals, and clinics, providing a competitive advantage in the market. The target industries include pharmaceutical manufacturing, healthcare services, and medical technology.